News

Currently, there are no glaucoma-specific instruments that estimate utilities across the spectrum of glaucoma severity.

Marc Bonaca, MD, discusses a new analysis of the VOYAGER PAD trial and implications for patients with diabetes and CLI.

Dennis Bruemmer, MD discusses new agents and perspectives on care in treating patients with type 2 diabetes at high risk of CV, renal complications.

Mortality rates differed significantly across the 3 clusters.

Investigators say that dietary habits in youth and young adult patients with diabetes can be impacted by income, employment, ethnicity, and a variety of other factors.

Methylphenidate hydrochloride (Adhansia XR) was originally approved in 2019 for ADHD patients at least 6 years old.

The treatment resulted in a significant reduction in expression of genes representing T & B lymphocytes, plasma cells/plasmablasts, and myeloid cells.

Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.

Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.

Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.

Only 5 patients treated with antibiotic prophylaxis developed bacteremia.

Researchers push for transparency between health care professionals and patients with diabetes about the safety and efficacy of the influenza vaccine

Misha Rosenbach, MD, mentions various ways dermatologists (and the population at large) can be more mindful of their impact on the environment

In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.

Investigative ORMD-0701 has potential to regulate the insulin-glucagon balance in patients.

Younger age and individuals who work more than 41 hours per week were associated with more prevalent mental health symptoms.

Changes in physical activity and diet may be main cause for worsening of diabetes control.

Data show similar family impact and distress scores at baseline and 3-months, highlighting continued impact of COVID-19 on T1D population.

Dr. Robert Baillieu discusses how the COVID-19 pandemic has specifically impacted patients dealing with addiction problems.

A longer time spent in hypoglycemia over a 24-hour period was associated with disrupted sleep among children with type 1 diabetes.

Matthew Budoff, MD highlights his own preferred methods of treatment and what might need to be done to help doctors and patients through the process.

The study shows a reduction in hemoglobin and a reduced risk of hypoglycemia in participants.

Of the two diabetes treatments included in the study, patients with Gla-300 had lower recorded total health costs and greater commitment to treatment.

Data show a 38% reduction in T2D incidence with dapagliflozin compared to placebo in patients with CKD.

Data show 66% of healthcare professionals reported greater confidence in prescribing SGLT2i, while 55% reported greater confidence in prescribing GLP-1.

Researchers found a significant interaction between SGLT2 inhibitors based on age and eGFR.

Fluid regulation is important to the prevention of heart failure.

Data show 37.5% of patients in study were found to have moderate to severe DD, with an average score of ≥2.